COMPANY UPDATES
25
Oct
2017
Novoheart strengthens North American presence opening new R&D location at the world-class Cove facility, Irvine, California

Novoheart (“Novoheart” or the “Company”) (TSXV: NVH), a global stem cell biotechnology company, is pleased to announce that it has opened a new US location in The Cove at Irvine, California. The Cove is home to UCI Applied Innovation - a public-private endeavour to accelerate the commercialization of technology and other world-class discoveries at UCI – as well as a number of renowned VC firms, entrepreneurs and fast-growth technology organizations. It features 46,000 square feet of state-of-the-art technological facilities and collaborative office space and offers Novoheart direct access to a number of strategic partners as well as to unique and innovative technologies and talent at the forefront of drug discovery.

Novoheart’s established presence in California marks a critical milestone in the Company’s early steps towards engaging the expansive North American market and supports its mission of positioning itself as a key player in the transformation of drug discovery.

“We are very excited to further expand our presence in North America and believe that working in The Cove provides an ideal environment to advance both our product and business development,” said Ronald Li, CEO of Novoheart. “The type of collaborative research between ours and UCI’s team clearly demonstrates the significant value of being in a state-of-the-art facility with other leading specialists. Having this type of validated research is incredibly important as we pursue our large-scale commercialization strategy and we believe that key, long-term, partnerships like those being established here will be a strong driver of our future success.”